Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Sponsor
Johann Wolfgang Goethe University Hospital
Study ID
NCT00802906
Status
Completed

Conditions

  • Central Serous Chorioretinopathy

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • subthreshold micropulselaser — DEVICE
    on demand if leakage is persistent or recurs after initial treatment
  • bevacizumab — DRUG
    1.5 mg initial intravitreal injection

Study Details

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

Key Dates

First listed
Dec 5, 2008
Start date
May 31, 2007
Status verified
Sep 2012
Primary completion
Nov 30, 2010
Completion
Dec 31, 2010

Study Design

Enrollment
12 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
  • Active Comparator: 2
    initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
  • No Intervention: 3
    control

Primary Outcome Measure

BCVA in EDTRS values [ Time Frame: 24 months ]

Related Studies